Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Medtronic Price Performance
Shares of NYSE:MDT opened at $95.24 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $127.77 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 2.44 and a beta of 0.75. Medtronic has a twelve month low of $86.70 and a twelve month high of $135.89. The business has a 50 day simple moving average of $91.05 and a 200-day simple moving average of $100.23.
Medtronic (NYSE:MDT - Get Rating) last issued its earnings results on Thursday, May 26th. The medical technology company reported $1.52 earnings per share for the quarter, missing analysts' consensus estimates of $1.56 by ($0.04). Medtronic had a return on equity of 14.50% and a net margin of 15.90%. The business had revenue of $8.09 billion for the quarter, compared to analyst estimates of $8.43 billion. During the same period last year, the company posted $1.50 earnings per share. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities research analysts expect that Medtronic will post 5.55 earnings per share for the current year.
Medtronic Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Stockholders of record on Friday, September 23rd will be given a dividend of $0.68 per share. This represents a $2.72 dividend on an annualized basis and a dividend yield of 2.86%. Medtronic's payout ratio is 72.92%.
Analyst Ratings Changes
A number of equities research analysts have issued reports on MDT shares. Sanford C. Bernstein reissued a "buy" rating and set a $122.00 price target on shares of Medtronic in a research report on Friday, May 20th. Cowen raised their price target on shares of Medtronic to $125.00 in a report on Monday, May 23rd. Piper Sandler reduced their price target on shares of Medtronic from $105.00 to $100.00 and set a "neutral" rating on the stock in a research report on Thursday, May 26th. Raymond James dropped their price objective on shares of Medtronic from $116.00 to $109.00 in a research report on Tuesday, May 31st. Finally, Cowen set a $125.00 target price on shares of Medtronic and gave the company an "outperform" rating in a report on Monday, May 23rd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $117.13.
